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Pharmacologic Inhibitors of Tumor Necrosis Factor Production Exert 
Differential Effects in Lethal Endotoxemia and in Infection with Live 
Microorganisms in Mice
Mihai G. Netea, Willem L. Blok, Bart-Jan Kuliberg, 
Marc Bemelmans, Maria T. E. Vogels, 
Wim A. Buurman, and Jos W. M. van der Meer
Department o f  Internal Medicine, University Hos pi ia I Nijmegen, 
Nijmegen, and Department o f  Surgery, University o f  Limburg,
Maastricht, Neiherlands
Tumor necrosis factor-a (TNF-a) and interleukin-1/? (IL-ljS) are principal mediators of septic 
shock; inhibition of TNF-a production may ameliorate outcome in severe infections. Pentoxifyl­
line, chlorpromazine, and thalidomide inhibit TNF-a production. Their effects were tested in 
lethal endotoxemia in sensitized mice, Only chlorpromazine significantly improved survival. 
Chlorpromazine and pentoxifylline significantly reduced postendotoxin circulating TNF-a, by 
89% and 76%, respectively. Chlorpromazine also significantly reduced IL-1/3 and soluble TN F 
receptor-P75. No drug improved survival in Klebsiella pneumoniae- infected mice despite signifi­
cantly lower circulating TNF-a concentrations in chlorpromazine- or pentoxifylline-treated ani­
mals. The three compounds decreased circulating TNF-a in Candida «/¿/caws-infected mice, but 
survival was not influenced. In neutropenic mice, chlorpromazine had no influence on candidae 
in organs, but in normal mice, Candida counts in kidneys were higher in chlorpromazine-treated 
mice. Thus, inhibition of TNF-a production was of no benefit in K  pneumoniae infection and 
worsened outcome in C. albicans infection.
The proinflammatory cytokines in te r leu k in -1 (IL -1 0 )  
and tumor necrosis factor-a (TNF-a) play an important role 
in the pathophysiology of sepsis [1]. TNF-a and IL-i/3 con­
centrations are increased early in sepsis, and clinical studies 
demonstrate that high concentrations ofTN F-a in the circu­
lation correlate with the seventy of the disease and with a 
poor prognosis [2, 3]. Treatment with anti-TN F-a antibod­
ies attenuates the lethal effects of endotoxin in mice and 
protects against shock after infusion of gram-negative bacte­
ria in primates [4, 5]. Similarly, treatment with either o f  the 
naturally occurring antagonists of IL-1 and TNF, IL-1 recep­
tor antagonist and soluble TN F receptor (sTNFR), has been 
shown effective in lethal endotoxemia and in various models 
of experimental infection [6-11], TNF-a also appears to 
have an important role in experimental Candida albicans in­
fection. The mannoprotein constituents o f  the Candida cell 
wall induce the in vitro production o f TNF-a by macro­
phages [12], and in vivo infusion of C, albicans in mice in­
duces a rise in TN F-a plasma concentrations, which peak at
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24 h [13]. Therefore, T N F -a  synthesis may be an important 
target for pharmacologic intervention in severe infections.
Pentoxifylline, a methylxanthine derivative and  phospho­
diesterase inhibitor, inhibits the generation o f mRNA for 
T N F-a  in vitro [14] and decreases the in vivo production of 
T N F-a  in humans and in experimental animals [15-17]. 
Pentoxifylline has been reported to increase survival o f  mice 
in endotoxic shock [16], Chlorpromazine is a phenothiazine 
derivative with a broad spectrum o f  actions that protects 
against the toxicity o f  endotoxin in various experimental 
models. At least part o f  this protection is achieved through 
inhibition o f T N F  synthesis [18]. Thalidomide has been used 
in the past as a sedative and  antiemetic drug. Because of its 
teratogenic effects it has limited use as an antiinflammatory 
and immunosuppressive agent in the treatm ent o f  erythema 
nodosum leprosum, rheumatoid arthritis, and severe graft- 
versus-host disease [ 19-21 ]. Thalidomide has been shown to 
inhibit T N F-a  production by monocytes when these cells are 
triggered with endotoxin [22].
In the present study, we evaluated to what extent treat­
ment with pentoxifylline, chlorpromazine, or thalidomide 
could increase survival after endotoxin challenge in sensi­
tized mice. W e measured circulating concentrations ofTNF- 
a, IL-1/3, and the two soluble T N F  receptors, sTNFR-P55 
and sTNFR-P75, after endotoxin challenge, We also evalu­
ated the effects o f  pentoxifylline, chlorpromazine and thali­
domide in lethal infections with Klebsiella pneumoniae or C. 
albicans. Because of the major im portance o f polymorphon­
uclear leukocytes in the defense against C. albicans [23] and 
their involvement in the actions o f  the cytokines during in­
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fection, we studied the effects o f  the drugs in normal and 
neutropenic mice infected with C. albicans.
Materials and Methods
Animals. Female Swiss mice, 6-8 weeks old, weight 20-25 
g, were obtained from a local colony. The animals were fed 
standard laboratory chow (Hope Farms, Woerden, Nether­
lands) and housed under specific pathogen-free conditions.
Drugs. Pentoxifylline was obtained from Hoechst Pharma 
(Frankfurt am Main, Germany). Chlorpromazine was obtained 
from Rhone-Poulenc Rorer (Amstelveen, Netherlands), and 
thalidomide was provided by K. Zwingenberger (Grunenthal, 
Sto 1 berg, Germany). Pentoxifylline (40 or 80 mg/kg) and chlor- 
promazine (4 mg/kg) were given in pyrogen-free saline by intra- 
peritoneal (ip) injection, since this is a convenient and effective 
route for administration of these compounds [16, 18]. Because 
no water-soluble form of thalidomide is available, this drug was 
given by gastric instillation in 1% carboxymethylcellulose at a 
dose of 400 mg/kg, Control mice received vehicle by the same 
route. Pentoxifylline and chlorpromazine were given 30 min 
and thalidomide 1 h before endotoxin injection. In the experi­
ments with live microorganisms, all treatments were started 1 
day before infection and continued daily thereafter, Pentoxifyl­
line was given at 80 mg/kg/day twice daily, chlorpromazine 4 
mg/kg/day once daily, and thalidomide 400 mg/kg/day once 
daily.
Lethal endotoxemia in sensitized mice. Lipopolysaccharide 
(LPS; Escherichia co!i serotype 055:85) was obtained from 
Sigma (St. Louis). Mice were sensitized with actinomycin D 
(Sigma) or D-galactosamine (Merck, Darmstadt, Germany). An­
imals were injected ip with actinomycin D (0.6 or 0.8 mg/kg) 10 
min before the ip injection of LPS (30 ^g/kg) as described [18]. 
In the experiments in which the mice were sensitized with D-ga­
lactosamine, the animals were given D-galactosamine (560 mg/ 
kg) and LPS (40 MgAg) simultaneously ip [24]. After injection 
of LPS, 6 mice from each treatment group were anesthetized 
with ether and bled from the retroorbital plexus at 90 min for 
measurement of circulating TNF-a concentrations and another 
6 mice per treatment group at 3 h for measurement of circulat­
ing concentrations of IL-1/3 and sTNFR-P55 and -P75, In the 
remaining mice, survival was assessed daily for 7 days.
K. pneumoniae infection. K. pneumoniae (ATCC 43816), a 
strain that produces a lethal infection in normal mice, was inocu­
lated in the left thigh muscle of the animals as described [25]. 
Tnocula ranged from 2 X 102 to 2 X 105 cfu. Twenty-four hours 
after infection, subgroups of mice were sacrificed and blood was 
collected for measurement of TNF-a plasma concentrations. To 
quantitate the recovery of the microorganisms from the livers 
and spleens, the organs were removed aseptically, weighed, and 
homogenized in sterile saline in a tissue grinder. To bring the 
bacterial counts after culture into the optimal range for reading, 
samples of liver and spleen were diluted in sterile saline. The 
suspensions were plated on sheep blood agar, and colony-form­
ing units were counted after overnight incubation. Survival of 
the animals was observed for 5 days after infection. In a separate 
experiment, the animals were infected with an inoculum of 104
cfu, and subgroups of 6 mice were sacrificed to measure TNF-a 
plasma concentrations at various time points after infection. In 
these animals, we measured the recovery of the microorganism 
from blood, liver, and spleen.
C. albicans infection. C. albicans (105 cfu) was given intrave­
nously (iv) in the lateral tail vein. At 24 h after injection, sub­
groups of mice were sacrificed, blood was taken for determina­
tion of plasma TNF-a concentrations, and the recovery of the 
microorganisms from livers, kidneys, and spleens was quanti­
tated in a manner similar to the quantitation of K. pneumoniae. 
Organ suspensions were plated on Sabouraud dextrose agar, and 
colonies were counted after overnight incubation. Survival of 
the animals was monitored for 8 days. In addition, mice ren­
dered granulocytopenic by subcutaneous injections of cyclo­
phosphamide, 150 mg/kg 4 days before and 100 mg/kg 1 day 
before infection, were injected with 104 cfu of C. albicans.
TNF-a measurement. Blood was collected in I-mL tubes 
containing 7.5 /igofEDTA (Becton Dickinson, Rutherford, NJ) 
and 250 ¡xL of aprotinin (Bayer, Leverkusen, Germany) and 
centrifuged for 5 min at 13,000 g. After separation, the plasma 
was stored at —20°C until assayed for TNF-a by ELISA. Briefly, 
96-well immunoassay plates were coated overnight at 4°C with 
V 1Q, a rat monoclonal antibody specific for mouse TNF-a (pro­
vided by Peter Krammer, Institute for Immunology and Genet­
ics, German Cancer Research Center, Heidelberg) [26]. Nonoc­
cupied binding sites were blocked with \% bovine serum 
albumin. The samples were added onto the plate for 1 h at room 
temperature. A standard titration curve was obtained by serial 
dilutions of a known sample of recombinant mouse TNF-a in 
medium identical to the samples. Plates were then washed four 
times with wash buffer and incubated with a rabbit anti-mouse 
polyclonal antibody and peroxidase-conjugated swine anti-rab­
bit IgG. After substrate was added for 18 min, the reaction was 
stopped with 4 M H2S 0 4, and photospectrometry (450 nm) was 
done. The lower detection limit was 300 pg/mL. In some of the 
experiments, ELISA was done with TN3 as the monoclonal an­
tibody directed against mouse TNF-« as described [27]. TN3 
was provided by Cell tech (Slough, UK) [28].
IL-Jj3 measurement. Plasma was collected in the same man­
ner as for TNF-ct measurement. IL-1/3 was measured on plasma 
samples obtained 3 h after LPS injection by specific RIA as 
described [29].
sTNFR measurement. Plasma was collected in the same 
manner as for TNF-a measurement. sTNFR-P55 and sTNFR- 
P75 were measured in plasma samples obtained 3 h after LPS 
injection by specific ELISA as described [30].
Statistical analysis. Survival curves were analyzed using the 
Kaplan-Meier logarithm of rank test [31]. Differences in con­
centrations of circulating cytokines and differences in organ 
counts of the microorganisms were analyzed using the Kruskal- 
Wallis test with x 2 approximation. Results were considered sta­
tistically significant at P < .05.
Results
Lethal endotoxemia in sensitized mice. Mortality oc­
curred in the first 48 h after endotoxin injection without
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further mortality during the next 5 days o f  follow-up. In the 
two models o f  endotoxin-induced mortality studied, actino- 
mycin D- and D-galactosamine-sensitized mice, treatment
K. pneumoniae infection. At 30 min after intramuscular 
(im) injection o f  104 cfu of K. pneumoniae, blood cultures 
were still sterile, and TNF-a was not detectable in the circu-
with chlorpromazine significantly improved survival (P  <  lation. However, at 90 min, TNF-a could be detected and 
.05), Treatment with pentoxifylline and thalidomide did not remained relatively constant during the observation period 
result in a better survival than control treatment (figure 1). (concentration range, ]. 1-3.3 ng/mL); from this time point
In a separate experiment in which treatment with pentoxifyl­
line was started 48 h before endotoxin challenge, survival of 
treated mice was not better than that o f  controls. Chlorpro­
mazine and pentoxifylline had a strong inhibitory effect on 
immunoreactive TN F-a concentrations in plasma 90 min 
after endotoxin, whereas thalidomide did not influence cir-
on, the microorganisms were present in the blood, liver, and 
spleen, indicating that there was an ongoing sepsis in these 
animals.
Plasma TN F-a concentrations at 24 h after infection were 
significantly decreased in the groups treated with pentoxifyl­
line and chlorpromazine compared with controls. Pentoxi-
A
dilating TNF-a (figure 2A), In actinomycin D-sensitized fylline reduced TN F-a by 22% (from 0,9 ± 0 . 1  to 0.7 ±  0.2 
mice, TNF-a concentrations did not differ significantly be- ng/mL, n ~  10, P <  .05), and chlorpromazine reduced TNF- 
tween the groups treated with pentoxifylline and chlorproma- a by 30% (0.5 ±  0.2 to 0.3 ±  0.07 ng/mL, n =  10, P <  .05). 
zine, but in mice sensitized with D-galactosamine, T N F-a  Although thalidomide reduced circulating T N F -a  concen- 
concentrations in chlorpromazine-treated mice were signifi­
cantly lower than in pentoxifylline-treated mice (P < ,01; 
results not shown),
The effects of the drugs on circulating IL-1 ¡3 concentra­
tions 3 h after endotoxin injection is shown in figure 2B.
Plasma IL-1/3 concentrations in chlorpromazine-treated 
mice were significantly lower than in control animals, but 
pentoxifylline and thalidomide did not influence circulating 
IL-1/3 concentrations.
None of the compounds influenced the concentrations of 
sTNFR-P55 3 h after endotoxin (not shown). However, 
chlorpromazine significantly decreased the concentration of 
sTNFR-P75 compared with controls (figure 2C).
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Figure 1. Percentage survival of D-galactosamine-sensitized 
Swiss mice after injection with lipopolysaccharide (n = 10, results 
of 1 representative experiment). P < .05 for chlorpromazine treat­
ment. In mice sensitized with actinomycin D, same trends were 
seen.
Figure 2. Circulating concentrations of cytokines after lipopoly­
saccharide (LPS) injection. A, TNF after 90 min (*P < .01 and P < 
.005 for pentoxifylline [POF] and chlorpromazine [CPZ], respec­
tively). B, Interleukin-1/3 (IL-1) after 3 h (*P <  .001 for CPZ). C, 
Soluble TNF receptor-P75 (sTNFR-P75) after 3 h (*P < .01 for 
CPZ). Results are mean ± SD (;? = 6). TLD, thalidomide.
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trations by 69%, this difference was not statistically signifi- ing TN F-a concentrations were substantially higher in neu-
cant because o f the large variation in the control group (con- tropenic mice than in nonneutropenic animals. Survival and
trols, 1.3 ±  1.5; thalidomide treatment, 0.4 ±  0.1 ng/mL; n recovery of C. albicans from the organs were not influenced
= 10). by any o f the drugs tested (figure 4).
Survival was not significantly improved by either drug.
Bacterial counts tended to be lower in the livers and spleens
of the treated animals, regardless o f  the drug used, but these Discussion
differences did not consistently reach statistical significance. 
Because chlorpromazine had the strongest effect on bacterial 
counts, we investigated the antimicrobial effect of chlorpro­
mazine in vitro. Chlorpromazine did not inhibit the growth 
o f  K. pneumoniae in vitro (data not shown).
C. albicans infection in nonneutropenic mice. Plasma 
TNF-o: concentrations were lower in chlorpromazine- and 
thalidomide-treated animals than in their respective con­
trols, while pentoxifylline was not able to inhibit TNF-o; pro­
duction significantly during this infection (figure 3A). Sur­
vival was not influenced by any o f the drugs used. Candidal 
outgrowth tended to be higher in pentoxifylline- and thalido­
mide-treated animals than in controls, but these differences 
were not statistically significant. However, chlorpromazine- 
treated animals showed significantly higher Candida counts 
in kidneys than did controls (figure 4).
C. albicans infection in neutropenic mice. Pentoxifylline 
significantly lowered plasma TNF-ct concentrations (figure 
3B). Chlorpromazine and thalidomide tended to inhibit 
TN F-a synthesis (P = .065 and .07, respectively). Circulât-
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Figure 3. TNF-ct plasma concentrations 24 h after injection of 
Candida albicans into nonneutropenic mice (A; *P < .05) or neu­
tropenic mice(B; *P< .05). POF, pentoxifylline; CPZ, chlorproma­
zine; TLD, thalidomide. Results are mean ± SD (n > 10 mice).
In this study we investigated the influence o f three pharma­
cologic inhibitors o f  TN F-a synthesis on outcome of lethal 
endotoxemia and infection. Endotoxin-induced mortality 
was studied in mice sensitized with D-galactosamine or actin- 
omycin D. Normal mice exhibit a low and varying sensitivity 
to endotoxin, thus hampering reproducibility o f  experi­
ments, Endotoxin-induced mortality in sensitized mice has 
been shown to be mediated by cytokine production [10, 18, 
24]. To rule out specific effects of either D-galactosamine or 
actinomycin D, both compounds were used in experiments 
with sensitized mice. We found that chlorpromazine was the 
most powerful inhibitor of postendotoxin TNF-o: production 
and the only one that increased survival in lethal endotoxe­
mia. Despite substantial reduction in T N F -a  production by 
pentoxifylline, this drug did not improve survival after endo­
toxin challenge in our experiments. Our findings with chlor­
promazine are in accordance with those of Gadina et al. [ 18], 
but despite equal and even higher dosage schedules of pen­
toxifylline used in our experiments, we could not confirm 
the data ofSchade et al. [16], who showed a beneficial effect 
o f  pentoxifylline on survival. These differences cannot 
readily be explained. Thalidomide appeared not to be an 
inhibitor of TN F-a production after in vivo administration of 
endotoxin. This finding underscores the differences in influ­
ence on cytokine production that may be observed in in vivo 
versus in vitro experiments [22]. However, thalidomide did 
decrease plasma TNF-o: concentrations after Candida infec­
tion in nonneutropenic mice. Differences in pharmacokinet­
ics between the orally administered thalidomide and ip chlor-
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Figure 4. Candida albicans outgrowth from kidneys of nonneu­
tropenic and neutropenic animals after treatment with chlorproma­
zine (CPZ) compared with controls. Results are mean ± SD; /? 5* 10 
mice. *P < .05.
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promazine and pentoxifylline may account for these diver­
gent effects.
Since pentoxifylline also substantially reduced postendo­
toxin circulating TN F-a concentrations, it is clear that re­
duction of TNF-a production cannot solely account for the 
beneficial effect ofchlorpromazine in lethal endotoxemia. In 
addition to substantially reducing TNF-a production, chlor- 
promazine profoundly decreased postendotoxin IL-10, and 
as far as we know this has not been reported before. As antag­
onism of IL-1 increases survival after lethal endotoxemia in 
mice [7], interference wilh the production of this cytokine 
may contribute to the effects observed. Chlorpromazine has 
a wide range of pharmacologic activities, from antipsychotic 
and antihistaminic actions [32] to inhibition o f phospholi- 
pase A2 [33]. To what extent these activities contribute to the 
effects in lethal endotoxemia is not clear. Pentoxifylline did 
not influence circulating IL-1/3 concentrations, a finding in 
accordance with reports that phosphodiesterase inhibitors, 
such as pentoxifylline, selectively decrease TNF-a: produc­
tion without affecting IL-1 production capacity [34].
It is of interest that chlorpromazine strongly reduced the 
concentration of circulating sTNFR-P75 at 3 h after endo­
toxin, without affecting the concentration of circulating 
sTNFR-P55. It was recently reported that injection of endo­
toxin in mice results in an increase in both sTNFR-P55 and 
sTNFR-P75 as early as 30 min after the injection. sTNFR- 
P55 slowly diminished after a peak 30 min after LPS, 
whereas sTNFR-P75 increased to a plateau concentration 
4-8 h after LPS administration [30]. Since both sTNFR-P55 
and sTNFR-P75 are well detectable in plasma 3 h after LPS 
injection, it is unlikely that we missed a difference in 
sTNFR-p55 concentrations induced by one of the com­
pounds. Recently, evidence was gained that in mice, 
sTNFR-P75 and not sTNFR-p55 is responsible for the inac­
tivation of TNF and clearance of the cytokine from the circu­
lation [35]. It is unlikely that the strong decrease in sTNFR- 
P75 induced by chlorpromazine is brought about by its 
inhibiting effect on the production of TNF-a or IL-1/3, since 
neither anti-TNF antibody nor IL-1 receptor antagonist de­
creased the concentration o f circulating sTNFR after endo­
toxin injection [30]. Thus, the mechanism by which chlor­
promazine reduces sTNFR-P75 concentration is probably 
more direct but remains to be elucidated.
From a clinical standpoint, it is somewhat worrisome that 
despite a marked inhibition of circulating TNF-a concentra­
tions, neither o f the drugs we tested improved outcome in K. 
pneumoniae infection. An infection with live microorgan­
isms gives rise to a much more complicated response of the 
host than an injection of LPS. After LPS injection, circulat­
ing TNF-a concentrations peak at 90 min and decrease rap­
idly thereafter [2]. As shown here, there is an ongoing release 
of TNF after im injection of K . pneumoniae. These data are 
in accordance with the observations of others regarding the
efficacy of anti-TNF antibodies in experimental E. coli infec­
tion: They may be protective after iv but no t after ip injec­
tion o f E. coli [36]. Thus, the lack o f  an effect o f  pharm aco­
logic TN F inhibition is reminiscent o f  the inability o f  
anti-TNF antibodies to improve outcom e in animal models 
o f  infection that resemble the gram-negative infection we 
have studied [4, 26, 37].
In C. albicans infection in mice, we found no influence o f  
the three drugs on the survival of the animals. A recent study 
also failed to show an effect of pentoxifylline on outcome o f  
infection wilh C. albicans in rats [17]. In our pentoxifylline- 
treated nonneutropenic mice, the concentrations o f  T N F-a  
tended to be reduced, but they were significantly inhibited 
only in the chlorpromazine- and thalidomide-treated groups. 
Only pentoxifylline significantly affected T N F -a  concentra­
tions in neutropenic mice. Since the same doses o f  pentoxi­
fylline and chlorpromazine did decrease T N F -a  synthesis in 
K. pneumoniae infection, these differences may be due to 
differences in the regulation of T N F-a  production in the two 
infection models. In this respect it should be m entioned that 
endotoxin does not induce TNF-a synthesis in endotoxin-re- 
sistant C3H/HeJ mice, while C. albicans does [13].
In nonneutropenic mice, chlorpromazine treatm ent was 
associated with an increased outgrowth o f  candidae from the 
kidneys, However, in neutropenic mice, none o f  the drugs 
tested influenced the recovery of the microorganisms from 
the organs. This observation is in accordance with the report 
by Steinshamn and Waage [38], who found that treatment 
with a monoclonal antibody against T N F -a  increased ou t­
growth o f  C  albicans from the kidneys o f  normal but not o f  
neutropenic mice. Taken together, these observations in in­
fection models are in agreement with the observations that 
TN F-a increases the intracellular killing o f  C  albicans by 
neutrophils in vitro [39, 40]. Apart from its influence on 
TN F production, direct interference with killing function o f  
neutrophils may also play a role in the increased candidal 
outgrowth in chlorpromazine-treated mice [41-43].
We conclude that chlorpromazine protects sensitized mice 
against death due to lethal endotoxemia and  that this protec­
tion is accompanied by a strong inhibition o f  in vivo T N F -a  
and IL-10 synthesis. The anticytokine effect o fch lo rp rom a­
zine may be counteracted by decreased concentrations of 
circulating sTNFR-P75. Pentoxifylline, chlorpromazine, 
and thalidomide do not improve survival in the models o f  
bacterial and fungal infections studied. In experimental in­
fections, which are probably more relevant for infections in 
humans than are LPS challenges, the capacity o f  the drugs 
tested to inhibit TNF-a production appeared limited, in the 
case of chlorpromazine, the potential benefit o f  reducing cir­
culating concentrations o f  TNF-a: in lethal infections seems 
to be counteracted by a reduced phagocytosing capacity o f 
neutrophils. In these experimental infections, the effects of
398 Netea et al. J ID  1995; 171 (February)
pharmacologic inhibition o f  TNF~<* production are reminis­
cent o f  the effects observed with antibodies to TNF-a.
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